文献速递系统性红斑狼疮

日本狼疮肾炎患者诱导治疗后的生活预后与肾脏复发

Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该回顾性研究分析了1993至2016年间140例狼疮肾炎患者,比较增殖性狼疮肾炎(PLN)与纯膜性狼疮肾炎(MLN)诱导治疗12个月后的完全缓解率、生活预后及肾脏复发。结果显示PLN与MLN的完全缓解率分别为50.5%和53.7%,生活预后(P=0.93)与肾脏复发(P=0.52)无显著差异,PLN中慢性化指数低和MLN中CH50水平高是12个月完全缓解的预测因素。

要点

  • PLN与MLN诱导治疗12个月完全缓解率分别为50.5%和53.7%。
  • PLN中慢性化指数低、MLN中CH50水平高预测12个月完全缓解。
  • PLN与MLN的生活预后(P=0.93)和肾脏复发(P=0.52)无显著差异。

核心结论

  • 诱导治疗后12个月完全缓解的预测因素在PLN为慢性化指数,在MLN为CH50水平。
  • PLN与MLN在生活预后和肾脏复发方面无显著差异。

研究设计与样本

  • 回顾性分析1993至2016年间140例经肾活检的狼疮肾炎患者,其中PLN 99例(70.7%),MLN 41例(29.3%)。

主要发现

  • PLN患者50例(50.5%)和MLN患者22例(53.7%)在12个月时达到完全缓解。
  • 多因素分析显示PLN中较低的慢性化指数和MLN中较高的CH50水平是12个月完全缓解的预测因素。
  • Kaplan-Meier分析显示PLN与MLN的生活预后(P=0.93)和肾脏复发(P=0.52)无显著差异。

关键数值与推荐

  • PLN定义为ISN/RPS III或IV型,MLN定义为ISN/RPS V型。
  • 完全缓解率在诱导治疗开始后12个月评估。

临床怎么用

  • 对于PLN患者,评估慢性化指数有助于预测诱导治疗12个月完全缓解的可能性。
  • 对于MLN患者,检测CH50水平有助于预测诱导治疗12个月完全缓解的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to compare life prognosis and renal relapse after induction therapy in proliferative (PLN) and pure membranous LN (MLN). METHODS: We retrospectively analysed the cases of 140 of 172 patients with LN who underwent a renal biopsy at our hospital or community hospitals from 1993 to 2016. We determined the complete response (CR) rate at 12 months after the patients had started induction therapy, and we evaluated the predictive factors for CR, life prognosis and renal relapse in PLN and pure MLN. We defined PLN as International Society of Neurology and the Renal Pathology Society (ISN/RPS) Class III or IV and MLN as ISN/RPS Class V. RESULTS: The renal pathology of 99 (70.7%) patients was classified as PLN, and that of the other 41 (29.3%) patients as MLN. Fifty patients (50.5%) with PLN and 22 patients (53.7%) with MLN achieved a CR at 12 months. A multivariate analysis showed that a lower index of chronicity in PLN and a higher total haemolytic complement (CH50) level in MLN were predictive factors for achieving a CR at 12 months. A Kaplan-Meier analysis showed that the life prognosis (P = 0.93) and renal relapse (P = 0.52) were not significantly different between PLN and MLN. CONCLUSIONS: The predictive factors for a CR at 12 months post-induction therapy were index of chronicity in PLN and CH50 level in MLN. There were no significant differences in life prognosis or renal relapse between PLN and MLN in the achievement of a CR at 12 months post-induction therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Okamoto M, Kitamura M, Sato S, et al. Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis. Rheumatology (Oxford). 2021. PMID: 33166998. doi:10.1093/rheumatology/keaa599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。